Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Biologics

Range of Insurance Issues Challenge Rheumatology

Thomas R. Collins  |  February 12, 2020

ACR representatives updated members on recent insurance issues…

Filed under:Uncategorized

Remembering Etanercept & the Advent of the Biologic Era

Robert S. Katz, MD  |  February 10, 2020

As a veteran rheumatologist, I remember the clinical trials of etanercept’s (Enbrel’s) efficacy. And when the drug was first approved in 1998, I participated in those clinical trials and realized the effectiveness was astonishing. It was easy to tell which patients were treated with etanercept vs. those who received placebo, even though both groups were…

Filed under:Biologics/DMARDsSpeak Out Rheum Tagged with:etanerceptSpeak Out Rheumatology

Tips for Smoothing the Time-Consuming Prior Authorization Process

Susan Bernstein  |  January 17, 2020

ATLANTA—Obtaining prior authorization to ensure services or prescription drugs are covered by a patient’s health plan consumes staff time, and delays or denials may cause patients to abandon treatment, according to speakers at the 2019 ACR/ARP Annual Meeting. In a session on Nov. 10, the experts shared tips to smooth the process. Train Staff on…

Filed under:Practice SupportWorkforce Tagged with:2019 ACR/ARP Annual Meetingpharmacy benefit managers (PBMs)prior authorizationstep therapy

What Should Providers Do to Address Polypharmacy?

Thomas R. Collins  |  January 17, 2020

ATLANTA—In a session at the 2019 ACR/ARP Annual Meeting, Susan Chrostowski, DNP, assistant clinical professor at Texas Woman’s University College of Nursing, Dallas, told the audience that she’d had a visit with a patient and asked how he was doing. “Not too good,” he said, explaining that his chest hurt. “What’s the matter with your…

Filed under:Patient Perspective Tagged with:2019 ACR/ARP Annual MeetingadherenceCenters for Medicare & Medicaid Services (CMS)Medication Theraphy Managementpolypharmacy

ACR Insurance Subcommittee Focuses on Coverage & Reimbursement

Ellen M. Gravallese, MD  |  January 16, 2020

On behalf of the ACR, I wish you happiness, prosperity and, above all, good health in this new decade. Now that the holidays are behind us and 2020 has launched, the ACR’s dedicated volunteers and staff are working collaboratively to achieve many ambitious initiatives to ensure the College’s dynamic and bright future. A few weeks…

Filed under:Legislation & AdvocacyPresident's Perspective Tagged with:Centers for Medicare & Medicaid Services (CMS)Insurance Subcommittee

New Consensus Recommendations Guide Sjögren’s Syndrome Management

Will Boggs, MD  |  November 25, 2019

NEW YORK (Reuters Health)—New consensus-based recommendations from the European League Against Rheumatism (EULAR) address the management of Sjögren’s syndrome with topical and systemic therapies. Sjögren’s syndrome presents with a broad spectrum of clinical manifestations and autoantibodies, including antinuclear antibodies (the most frequently detected), anti-Ro/SS-A (the most specific) and cryoglobulins and hypocomplementemia (the main prognostic markers)….

Filed under:ConditionsEULAR/OtherMeeting ReportsSjögren’s Disease Tagged with:EULARguidelinerecommendationsSjogren's

The ARP Aids Rheumatology Workforce Expansion Via Online Education

Benjamin J. Smith, PA-C, DFAAPA, Sonam Kiwalkar, MD, & Aileen Ledingham, PT, PhD, on behalf of the ARP eLearning subcommittee  |  November 17, 2019

The Advanced Rheumatology Course (ARC) carries the distinction of being the first online educational product of the ACR/ARP. In the early 2000s, members of the College thoughtfully considered action needed to efficiently prepare health professionals looking to enter the rheumatology workforce. A decision was made to create online educational products with the specific target audience…

Filed under:Education & TrainingFrom the College Tagged with:Advanced Rheumatology Course (ARC)eLearningnurse practitionerphysician assistants

The 2019 ARP Awards of Distinction & ACR Masters

Carol Patton, with Keri Losavio  |  November 16, 2019

ATLANTA—At the 2019 ACR/ARP Annual Meeting in November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist speaks with the winners of the ARP Merit Awards about their individual contributions to advancing rheumatology. You’ll also find a…

Filed under:Awards Tagged with:2019 ACR/ARP Annual MeetingAnnelle ReedAssociation of Rheumatology Professionals (ARP)Dana GuglielmoDr. Calvin R. Brown Jr.Dr. Carlos PinedaDr. Chester V. OddisDr. Fredrica E. SmithDr. Gerd R. BurmesterDr. Geri NeubergerDr. Grant W. CannonDr. Hani El-GabalawyDr. J. Lee NelsonDr. James N. JarvisDr. John D. ReveilleDr. John J. O’SheaDr. Jonathan S. CoblynDr. Jürgen BraunDr. Lee Stuart SimonDr. Linda Kay MyersDr. Michelle A. PetriDr. Nighat Mir AhmadDr. Ronald M. LaxerDr. Rosalind Ramsey-GoldmanDr. Rowland W. ChangDr. Sharad LakhanpalDr. Simon HelfgottDr. William F.C. RigbyHeather BenhamJoni DeanMichael LaValleyMonique GignacRobert Richardson

Do Patients with Ankylosing Spondylitis in Remission Still Need TNF Inhibitors?

Lara C. Pullen, PhD  |  October 24, 2019

Patients with axial spondyloarthritis have a chronic, immune-mediated inflammatory disease that tends to localize to the sacroiliac joints and spine. Ankylosing spondylitis is, perhaps, the most representative of this group of diseases. Rheumatologists treat patients with axial spondyloarthritis with biologics, such as tumor necrosis factor inhibitors (TNFi’s), which can improve quality of life, activity and…

Filed under:Axial SpondyloarthritisConditionsResearch Rheum Tagged with:Ankylosing SpondylitisRemissionTNF inhibitors

Case Report: A Patient on Apremilast Develops Streptococcus Salivarius

Stephanie Kydd Dondero, DO, & Barry Waters, MD  |  October 18, 2019

Apremilast was first marketed in March 2014 for the treatment of adults with psoriatic arthritis (PsA). An immuno­modulating drug, which is a small molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine mono­phosphate (cAMP), apremilast is administered orally. By inhibiting PDE4, intracellular cAMP levels are increased. Although the exact mechanism of action is not…

Filed under:Conditions Tagged with:apremilastcase reportimmunosuppressive drugsStreptococcus salivarius

  • « Previous Page
  • 1
  • …
  • 27
  • 28
  • 29
  • 30
  • 31
  • …
  • 75
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences